ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - Update on methodological approaches and results interpretation

J Malcikova, E Tausch, D Rossi, LA Sutton, T Soussi, T Zenz, AP Kater, CU Niemann, D Gonzalez, F Davi, M Gonzalez Diaz, C. Moreno, G Gaidano, K Stamatopoulos, R Rosenquist, S Stilgenbauer, P Ghia, S Pospisilova, on behalf of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) - TP53 network

Research output: Contribution to journalArticlepeer-review

Abstract

In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. On these grounds, analysis of TP53 aberrations has been incorporated into routine clinical diagnostics to improve patient stratification and optimize therapeutic decisions. The predictive implications of TP53 aberrations have increasing significance in the era of novel targeted therapies, i.e., inhibitors of B-cell receptor (BcR) signaling and anti-apoptotic BCL2 family members, owing to their efficacy in patients with TP53 defects. In this report, the TP53 Network of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) presents updated recommendations on the methodological approaches for TP53 mutation analysis. Moreover, it provides guidance to ensure that the analysis is performed in a timely manner for all patients requiring treatment and that the data is interpreted and reported in a consistent, standardized, and accurate way. Since next-generation sequencing technologies are gaining prominence within diagnostic laboratories, this report also offers advice and recommendations for the interpretation of TP53 mutation data generated by this methodology. © 2018 The Author(s).
Original languageEnglish
Pages (from-to)1070-1080
Number of pages11
JournalLeukemia
Volume32
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia - Update on methodological approaches and results interpretation'. Together they form a unique fingerprint.

Cite this